GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » Net Margin %

NeuroPace (NeuroPace) Net Margin % : -34.42% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeuroPace Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. NeuroPace's Net Income for the three months ended in Dec. 2023 was $-6.20 Mil. NeuroPace's Revenue for the three months ended in Dec. 2023 was $18.01 Mil. Therefore, NeuroPace's net margin for the quarter that ended in Dec. 2023 was -34.42%.

The historical rank and industry rank for NeuroPace's Net Margin % or its related term are showing as below:

NPCE' s Net Margin % Range Over the Past 10 Years
Min: -103.43   Med: -79.85   Max: -50.38
Current: -50.38


NPCE's Net Margin % is ranked worse than
69.9% of 814 companies
in the Medical Devices & Instruments industry
Industry Median: -0.41 vs NPCE: -50.38

NeuroPace Net Margin % Historical Data

The historical data trend for NeuroPace's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace Net Margin % Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
-81.07 -59.02 -79.85 -103.43 -50.38

NeuroPace Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.15 -71.69 -55.26 -44.18 -34.42

Competitive Comparison of NeuroPace's Net Margin %

For the Medical Devices subindustry, NeuroPace's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroPace's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Net Margin % distribution charts can be found below:

* The bar in red indicates where NeuroPace's Net Margin % falls into.



NeuroPace Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

NeuroPace's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-32.956/65.421
=-50.38 %

NeuroPace's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-6.2/18.012
=-34.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroPace  (NAS:NPCE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


NeuroPace Net Margin % Related Terms

Thank you for viewing the detailed overview of NeuroPace's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroPace (NeuroPace) Business Description

Traded in Other Exchanges
N/A
Address
455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Executives
Martha Morrell officer: Chief Medical officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd. 10 percent owner CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker director, officer: Chief Executive Officer ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley officer: General Counsel and Secretary C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade director 6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield director C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer director 9701 JERONIMO, IRVINE CA 92618
Evan Norton director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob director 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet director, officer: Chief Executive Officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043